Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Beats Revenue Estimates

分组1 - Agios Pharmaceuticals reported a quarterly loss of $1.85 per share, which was better than the Zacks Consensus Estimate of a loss of $1.97, representing an earnings surprise of +6.25% [1] - The company posted revenues of $19.97 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 94.14%, compared to revenues of $10.73 million a year ago [2] - Over the last four quarters, Agios Pharmaceuticals has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times [2] 分组2 - The stock has gained about 1.8% since the beginning of the year, outperforming the S&P 500's gain of 1.4% [3] - The current consensus EPS estimate for the coming quarter is -$1.80 on revenues of $12.52 million, and for the current fiscal year, it is -$6.77 on revenues of $79 million [7] - The Medical - Biomedical and Genetics industry, to which Agios Pharmaceuticals belongs, is currently in the top 36% of Zacks industries, indicating a favorable outlook [8]